Progression of Liver Damage and Cardiometabolic Disorders in Non-alcoholic Fatty Liver Disease: an Observational Cohort Study The Plinio Study

What this Trial Is About

This research aims to investigate factors related to liver fibrosis progression and cardiovascular risks in people with non-alcoholic fatty liver disease (NAFLD). NAFLD is a common liver condition ranging from simple fat buildup to severe liver damage including cirrhosis and cancer. The study focuses on understanding how biochemical and genetic factors, alongside known conditions like diabetes and specific gene mutations, influence fibrosis evolution and cardiovascular events in a large group of patients with fatty liver disease diagnosed by ultrasound. Participants will not receive treatments as this is an observational study. Researchers will track fibrosis progression using noninvasive scores such as NAFLD fibrosis score and Fibrosis-4 over an average of 10 years. The study will also explore the relationship between NAFLD and cardiovascular events, looking at various biochemical markers, nutritional factors, and genetic influences at baseline and during follow-up. Secondary outcomes include evaluating kidney disease progression and cardiovascular risk scores. During the study, participants will undergo regular clinical, biochemical, and genetic evaluations. Assessments will include measurements of liver fibrosis progression, cardiovascular risk, oxidative stress markers, and gut microbiota analysis. Follow-up is expected to last around 10 years for fibrosis progression and cardiovascular outcomes, with some measures assessed at baseline. The study will monitor health outcomes without intervention to better understand the natural course of NAFLD and related disorders.

Liver Damage and Cardiometabolic Disorders in NAFLD